TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model

Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall & Jack A. Roth

KRAS/LKB1 (STK11) NSCLC metastatic tumors are intrinsically resistant to anti-PD-1 or PD-L1 immunotherapy. In this study, we use a humanized mouse model to show that while carboplatin plus pembrolizumab reduce tumor growth moderately and transiently, the addition of the tumor suppressor gene TUSC2, delivered systemically in nanovesicles, to this combination, eradicates tumors in the majority of animals. Immunoprofiling of the tumor microenvironment shows the addition of TUSC2 mediates: (a) significant infiltration of reconstituted human functional cytotoxic T cells, natural killer cells, and dendritic cells; (b) induction of antigen-specific T cell responses; (c) enrichment of functional central and memory effector T cells; and (d) decreased levels of PD-1+ T cells, myeloid-derived suppressor cells, Tregs, and M2 tumor associated macrophages. Depletion studies show the presence of functional central and memory effector T cells are required for the efficacy. TUSC2 sensitizes KRAS/LKB1 tumors to carboplatin plus pembrolizumab through modulation of the immune contexture towards a pro-immune tumor microenvironment.
Approximately half of NSCLC patients with activating KRAS mutations have deletions or inactivating mutations in the serine/threonine kinase 11 gene, STK11 (LKB1)\textsuperscript{1,2}. The co-occurrence of KRAS mutation and LKB1 loss (KL) is associated with poor prognosis, due to an increase in metastatic burden and resistance to therapy\textsuperscript{3,4}. Cytotoxic chemotherapy was the standard of care for the majority of patients diagnosed with metastatic NSCLC, irrespective of the histological subtype until the recent approval of immune checkpoint blockade therapy (ICB)\textsuperscript{5}. Currently, chemotherapy plus ICB or ICB alone (if PD-L1 is >50\%) has been used as a first-line treatment for metastatic NSCLC. Carboplatin with pemetrexed/Nab-Paclitaxel combined with pembrolizumab/Atezolizumab improved overall survival (OS) relative to chemotherapy alone in both adenocarcinoma and squamous cancers\textsuperscript{6,7}. Monoimmunotherapy only shows clinical benefit among patients with higher programmed death protein ligand 1 (PD-L1) expression and with no oncogenic driver mutations such as EGFR, ALK, or ROS1. Worse OS and progression-free survival (PFS) outcomes were found in patients with KL subtypes receiving chemotherapy and immunotherapy alone, or in combination, as compared with their wild-type groups\textsuperscript{8}.

TUSC2, a tumor suppression gene, is completely absent or weakly expressed in the majority of NSCLC. TUSC2 is multifactorial in its mechanism of action and regulates a wide array of cellular processes, including apoptosis induction through broad multit kinase inhibition and immune-system stimulation. We have recently established the role of TUSC2 in activating innate and adaptive immunity. TUSC2 selectively augments natural killer (NK) cells and cytotoxic T lymphocyte (CTL) activity in peripheral blood and in the tumor microenvironment and induces a Th1-mediated immune response, as well as downregulates myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg)\textsuperscript{8}. We also showed that TUSC2 restoration downregulates PD-L1 expression in NSCLC and synergizes with anti-PD-1 in syngeneic KRAS mutant lung cancer mouse models\textsuperscript{8,9}. A phase I study showed the safety of nanovesicle mediated-TUSC2 delivery\textsuperscript{10}. TUSC2 nanovesicles work synergistically with tyrosine kinase inhibitors (TKIs), such as EGFR and AKT inhibitors, erlotinib, and M2206, respectively, through downregulating the oncogenic PI3K/Akt/mTOR pathway\textsuperscript{11,12}. Inhibition of the latter was shown to induce expansion of tumor infiltrated lymphocytes (TILs), promoting a memory T cell phenotype\textsuperscript{13}. Currently, an opened clinical trial evaluating TUSC2 synergy with a third TKI generation, osimertinib, is recruiting NSCLC patients (ClinicalTrials.gov Identifier: NCT04486833).

We recently developed an improved humanized mouse model using fresh human umbilical cord blood derived CD34\textsuperscript{+} stem cells\textsuperscript{14}. The reconstituted humanized mice have a fully competent human immune system with major functional immune populations, which showed antigen-specific T cell responses as well as antitumor activity with immune checkpoint blockade therapy. This model provides a unique opportunity for establishing an effective drug screening workflow for immunotherapy.

Standard chemo–immunotherapy combination therapy is much less effective against NSCLC KL subtypes due to their impaired immunogenicity\textsuperscript{14}. Silencing of STING signaling was found to be associated with immune evasion in KL cells, which might impair innate activation and antigen presentation\textsuperscript{15}. In this study, we tested the hypothesis that modulation of the tumor immune microenvironment by TUSC2 immunogene therapy, which induces apoptosis in tumor cells and promotes a variety of innate and adaptive immune responses such as release of tumor-associated antigen, antigen processing and presentation, CTL responses, would alter the outcome of chemo–immunotherapy combination in a humanized mouse model implanted with KL A549 xenografts. A robust antitumor activity was found, which was significantly superior to a standard chemo–immunotherapy combination. The efficacy was associated with induction of an antitumor immune response through generating functionally active central and effector memory T cells.

**Results**

**Carboplatin plus pembrolizumab induces transient antitumor activity.** Humanized mice implanted with KL A549 xenografts were treated with carboplatin combined with pembrolizumab to assess the antitumor efficacy of this model. Since KL NSCLC patients are not responsive to this combination, a similar result was predicted in this model. Fresh CD34 stem cell derived humanized mice developed from different cord blood donors were randomized into different experimental arms. Figure 1a shows the average percentage levels of human reconstituted CD45\textsuperscript{+} T, B, NK, and DC cells in mice, 5 weeks post CD34 engraftment, as characterized by multicolor flow cytometry. Cord blood from different donors were typed for the most common HLA-A and HLA-B loci (Fig. 1b). A549 cells exhibited low expression of MHC I and no expression of MHC II (Fig. 1c). The representative scatter plot shows human immune cell reconstitution status immediately before treatment was initiated.

Mice were repopulated with over 90% human CD45\textsuperscript{+} leukocytes, about 30% T lymphocytes, and 10–15% NK cells (Fig. 1d) after initial engraftment. Lung metastases were initiated by intravenous injection of KL mutant A549 cells. Mice were treated with pembrolizumab (250 μg/mouse) and carboplatin (10 mg/kg) according to the treatment strategy shown in Fig. 1e. Two weeks posttreatment, pembrolizumab monotherapy and carboplatin plus pembrolizumab combination had similar antitumor efficacy (\(P < 0.05\); \(P < 0.005\)) (Fig. 1g). Tumors were reduced significantly when compared to control and carboplatin alone. At week 3, efficacy of the combination was superior to that of carboplatin or pembrolizumab monotherapies (\(P < 0.005\)) (Fig. 1h). Pembrolizumab efficacy was diminished at week 3, whereas carboplatin did not reduce tumor growth until week 3, \(P < 0.05\) (Fig. 1f–i). After the third week, tumors were no longer responsive to the combination or to both single agents, and continued progressive growth (Fig. 1j, k). These results validate this model as similar response trends occurred in KL NSCLC patients treated with carboplatin, pembrolizumab, or the combination of both with a non-durable response followed by tumor regrowth.

**TUSC2 synergizes with pembrolizumab.** We have previously shown that the combination of TUSC2 and anti-PD1 inhibited tumor growth synergistically in subcutaneous and metastatic NSCLC KRAS mutant syngeneic mouse models (8). To determine whether this synergy also applies to the KL subtype, humanized mice harboring KL A549 lung metastases were treated with TUSC2, pembrolizumab, or the combination. The TUSC2 gene was packaged in DOTAP-cholesterol(DC) nanovesicles for intravenous systemic delivery (at a dose of 25 μg of plasmid DNA, 10 nmol DC in 100 μL of 5% dextrose in water every 48 h for a total of three injections). The treatment strategies are shown in Fig. 2a. Both TUSC2 and pembrolizumab monotherapies reduced the tumor burden significantly, \(P < 0.05\), although pembrolizumab was moderately more effective. TUSC2 plus pembrolizumab inhibited tumor growth synergistically, \(P < 0.0005\) (Fig. 2b, c). There was no antitumor effect of pembrolizumab in non-humanized mice. TUSC2 also showed synergistic antitumor activity with nivolumab in the same model (Supplement Fig. 1), highlighting the role of TUSC2 in rendering KL tumors more sensitive to immune checkpoint blockade.

To identify the immunological features associated with efficacy of this combination, we performed in-depth immune profiling of
Fig. 1 Effect of chemo-immunotherapy combination on KRAS/LKB1 mutant lung metastasis in humanized mice. a NSG mice were humanized through human CD34+ stem cells implantation into irradiated mice and the level of reconstitution of human immune cells into mice system after 5 weeks of post-humanization is shown. b Human HLA typing results of both HLA-A and HLA-B locus of umbilical cord blood donors. c Expression level of MHC class I and II on KRAS/LKB1 mutant cancer cell line. The level of expression of MHC I and MHC II on A549 was determined based on the expression level on PBMCs, which is used as a positive control in the experiment. d Scatter plot analysis to show the level of major human immune cells in humanized mice. A hundred microliters of blood collected from tail vein and immune cells were stained and analyzed by flow cytometry. e Treatment strategy where 7–8 weeks post humanized mice were implanted with tumors and lung metastases were treated with carboplatin (10 mg/kg) every other day (purple arrow) for 2 weeks and pembrolizumab (250 ug/mouse) every 3–4 days for 3X (green arrow). f Small animal imaging was done by IVIS 200 to determine the bioluminescence signal from tumor cells at week 2. g, h Quantitative analysis of tumor intensity determined from IVIS imaging at week 2 and week 3 respectively. i IVIS imaging of tumor-bearing humanized mice in different treatment groups at week 3. j Tumor growth curve shows the growth of lung metastasis and the response to the treatment at different time points. k Tumor growth curve comparison between carboplatin alone and carboplatin + pembrolizumab combination treatment groups at extended time points. The results shown are from one of three independent experiments with similar results; bars, SD. *P < 0.05, **P < 0.005, ***P < 0.0005.
the tumor microenvironment. An increased number of reconstituted human CD3$^+$ T cells was found in all groups, compared with the untreated control. CD8$^+$ T cells were significantly upregulated (*$P$ < 0.05) by pembrolizumab and its combination with TUSC2 (Fig. 2d). Levels of activated CD8$^+$ T cells (CD8$^+$CD69$^+$) were also significantly increased in the combination group (*$P$ < 0.05), indicating TUSC2 regulation of NK activation, which is consistent with our previous finding reported in syngeneic mice$^8$. The combination had a similar effect as TUSC2 monotherapy (Fig. 2e). TUSC2, pembrolizumab, and the combination, were all associated with significant decrease of reconstituted human MDSCs (CD33$^+$ve), *$P$ < 0.05, **$P$ < 0.005 (Fig. 2f). Pembrolizumab and the combination had a profound stimulatory effect on HLA-DR$^+$ DCs, *$P$ < 0.05 (Fig. 2g). TUSC2 restored expression alone enhanced HLA-DR$^+$ DC levels moderately. Taken together, the result shows that the combination of TUSC2 and pembrolizumab inhibited tumor growth synergistically, a response that was significantly more effective and durable than that of carboplatin plus pembrolizumab.

**TUSC2 plus carboplatin and pembrolizumab combination eradicates KL tumors.** TUSC2 was then added to the carboplatin and pembrolizumab combination. NSG mouse humanization and treatment protocol strategies are shown in Fig. 3a. TUSC2 plus pembrolizumab and carboplatin plus pembrolizumab dual combinations were used as controls. We found that TUSC2 inhibited tumor growth to the same extent as carboplatin plus pembrolizumab (Fig. 3b–d). TUSC2 combination with pembrolizumab and carboplatin eradicated tumors completely in some mice, *$P$ < 0.05. Bioluminescence imaging showed five out of seven humanized mice with no tumor burden at week 5 (Fig. 3b). The other two less responsive tumors did exhibit more growth inhibition than those in the carboplatin plus pembrolizumab group. The percentage change in tumor intensity between weeks 2 and 5 showed that the triple agent treatment significantly reduced or eradicated tumors as compared with the chemo–immunotherapy combination, Fig. 3d (**$P$ < 0.0005). Individual growth curves showed that all mice in the triple treatment group had little or no tumor signal in lung (Fig. 3e). Complete tumor eradication was validated in several independent experiments (Fig. 3f, supplement Fig. 2). The results clearly demonstrate that restoration of TUSC2 expression profoundly enhances KL tumor response to conventional chemo–immunotherapy. This triple combination also

---

**Fig. 2** Synergistic antitumor effect of TUSC2 immunogene therapy with pembrolizumab on KRAS/LKB1 lung metastases in the humanized mouse model. **a** Treatment strategy shows that tumors were implanted into 6–7 weeks post humanized mice and lung metastasis were treated with TUSC2 injection through i.v. (25 ug/mouse) on every 3 days for 3X and pembrolizumab (250 ug/mouse) on every 3–4 days for 3X. **b** Tumor-bearing humanized mice were images by IVIS 200 and tumor intensity was measured and quantitated and level of tumor reduction by treatment was shown in both humanized and non-humanized mouse models. **c** Bioluminescence imaging of performed by IVIS 200 to visualize the intensity of tumor burden on mice in different treatment groups both in humanized mice and non-humanized mouse system. This experiment was repeated three times with 7–8 mice/group used in each experiment, bars, SD. *$P$ < 0.05, **$P$ < 0.005, ***$P$ < 0.0005. **d** Tumors were analyzed through single cells preparation and stained for human T and activated T cells in tumor microenvironment. **e** Infiltrating NK and activating NK cells were analyzed in tumors. **f**, **g** Level of MDSC and HLA-DR$^+$ DC in tumor were determined through flow cytometry analysis of tumor tissues. Data are shown as mean percentage ± SD, n = 5. *$P$ < 0.05, **$P$ < 0.005, ***$P$ < 0.0005.
induced strong antitumor immune responses in a highly aggressive aPD1 resistant KRAS mutant (G12V) CMT167 syngeneic mouse model (supplement Fig. 5).

Efficacy of TUSC2 plus carboplatin and pembrolizumab combination is associated with an increase in immune-stimulatory cells within the TME. To characterize the immunological impact of this triple agent combination, we profiled major reconstituted human immune populations in the tumor microenvironment in humanized mice by flow cytometry. Immunological features of the triple agent combination were compared with those of the dual treatments. As Fig. 4a–h show, the triple combination was associated with a significant increase number of reconstituted human (a) CD45+ (**P < 0.005 vs control; *P < 0.05 vs TUSC2; ***P < 0.0005 vs carboplatin + pembrolizumab); (b) CD3+ T (*P < 0.05 vs control, *P < 0.05 vs carboplatin + pembrolizumab); (c) CD8+ T (**P < 0.005 vs control, *P < 0.05 vs TUSC2); (d) NK effector cells (**P < 0.005 vs control, *P < 0.05 vs carboplatin + pembrolizumab); (e) tumor infiltrated active T cells (CD3+CD69+, CD4+CD69+, CD8+CD69+); (f) tissue resident memory T cells (CD3+CD103+, CD4+CD103+, CD8+CD103+); and (g) dendritic cells, DC (HLA-DR+, CD86, CD40, and CD11c). Maturation on DCs by the triple agent combination is shown in supplement Fig. 3.

TUSC2 intravenous injection enhanced levels of CD45+ and CD8+ T cells significantly, although not to the extent of TUSC2 plus pembrolizumab or carboplatin plus pembrolizumab. TUSC2 had a profound stimulatory effect on the active NK cell population alone and when combined with other agents, validating NK stimulation by TUSC2, which we recently reported8. TUSC2 plus pembrolizumab was associated with better activation of CD45+ and CD8+ T cells.
Tcells, CD3⁺ Tcell, CD8⁺ Tcell, and NK cells than carboplatin plus pembrolizumab. The data show that in the TME, the triple agent combination promotes a potent antitumor immunity, which is mediated largely by tumor infiltrating active lymphocytes, NK cells, and DC.

Efficacy of TUSC2 plus carboplatin and pembrolizumab combination is associated with a significant decrease of immunosuppressive cells within the TME. The triple combination was also associated with a significant decrease of reconstituted tumor-infiltrating human immunosuppressive cells.
Fig. 4 Antitumor immune response mediated by carboplatin + pembrolizumab + TUSC2 combination on KRAS/LKB1 lung metastases in the humanized mouse model. a-d Lung metastases tissues were analyzed for infiltrating human immune cells. Single-cell suspensions were prepared from fresh lung metastases and in-depth immune analyses were performed using flow cytometry for determining human CD45+ leukocytes, CD3+ T, CD8+ T, and NK, cells. The level of human immune cells are shown for different treatment groups. e Level of activating CD3+ T, CD4+ T, and CD8+ T cells were determined by the expression of CD69 expressing markers on infiltrating T cells among different treatment groups. f Percentages of tissue-resident T cells (TRM) in tumors and their alteration by triple agent treatment. CD103+ expressing T cells were considered as TRM. g Level of HLA-DR + DC cells was determined among the lineage-negative population. h Maturated CD11c positive DC were determined based on subsequent gating on CD11b+ > CD11c+ > HLA-DR+ and the level of alteration of CD11c DC were shown under different treatments. Statistics are shown at a significance level of p < 0.05 unless otherwise noted. Data are shown as mean percentage ± SD, n = 5. **P < 0.005, ***P < 0.0005.

These include: (a) regulatory T cells (Treg) (Fig. 5a, b), as demonstrated by the higher effector/Treg ratio (***P < 0.005 vs control, *P < 0.05 vs TUSC2); (b) PD1+ T cells (CD3+CD274+ T, CD4+CD274+ T, CD8+CD274+ T) (Fig. 5c); (c) myeloid-derived suppressor cells (MDSC) (Fig. 5d); and (d) M2 tumor associated macrophages (TAMs), (Fig. 5e) These results indicate that the triple combination diminishes the immunosuppressive TME, mediated largely by tumor-infiltrating MDSCs, TAMs and Tregs, significantly more than TUSC2 plus pembrolizumab or carboplatin plus pembrolizumab.

Efficacy of the TUSC2 plus carboplatin and pembrolizumab combination is associated with a significant increase of functionally active memory T cells. We evaluated the distribution and alteration of effector memory (EM) (CD3+CD8+CD45RA−CCR7−), central memory (CM) (CD3+CD8+CD45RA−CCR7+), and naïve (TNaive) (CD3+CD8+CD45RA+CCR7+) T cells. CD3+ and CD8+ CM and EM populations were significantly increased following triple combination treatment compared with carboplatin plus pembrolizumab and TUSC2 plus pembrolizumab (CD3+CM, ***P < 0.0005; CD3+EM, *P < 0.05; CD8+CM, ***P < 0.0005; CD8+EM, *P < 0.05) (Fig. 6a–c). In contrast, both CD3+ and CD8+ Naive T cells (TNaive) were significantly less prevalent in the triple agent treatment group, compared with the carboplatin plus pembrolizumab (CD3+ TNaive, ***P < 0.005 vs carboplatin + pembrolizumab, ***P < 0.005 vs control; CD8+ TNaive, *P < 0.05 vs carboplatin + pembrolizumab, ***P < 0.0005 vs control) (Fig. 6d, e).

In-vitro activation of T cells derived from tumors, and stimulated with PMA, resulted in a significant release of IFN-γ by CD3+, CD4+, and CD8+ T cells, regardless of the treatment group, indicating that these T cells are functionally active (Fig. 6d–f). Analysis of IFN-γ expression by tumor-infiltrating CD3+, CD4+, and CD8+ central and effector memory T cells
revealed a significantly higher level in the triple combination (CD3+/CD4+ CM, **P < 0.005 vs carboplatin + pembrolizumab; CD8+ CM, *P < 0.05 vs carboplatin + pembrolizumab), (CD3+ EM, *P < 0.05, CD4+ EM, **P < 0.005, CD8+ EM, *P < 0.05) (Fig. 6i-k). TUSC2 plus pembrolizumab showed the second-largest increase in activating memory T cells, which was consistent with its antitumor activity shown in Fig. 3f. Thus, the triple agent combination yielded the highest number of functionally central and effector memory T cells in the tumor microenvironment.

TUSC2+ carboplatin and pembrolizumab increased central and effector memory T cell-dependent antigen-specific responses. To assess antigen-specific T cell responses following treatment, T cells were harvested from tumor-bearing humanized mice and co-cultured with KL A549 cells, and intracellular IFN-γ expression was measured in vitro (Fig. 7a). Scatter plots show the gating of IFN-γ+ T cells for T cells in co-cultures with A549 cells, which showed a significant increase in all treatment groups compared to control, (*P < 0.05 vs TUSC2, **P < 0.005 vs carboplatin + pembrolizumab, ***P < 0.005 vs TUSC2 + pembrolizumab) (Fig. 7c). However, increases of CD3+ IFN-γ+ and CD8+ IFN-γ+ T cells were the highest in the triple agent treatment group, *P < 0.05 (Fig. 7c). There was no IFN-γ+ T cell expression when T cells were not stimulated or co-cultured with HBE cells, indicating that the observed T cell responses with A549 co-culture were antigen-specific (Fig. 7c).

Finally, to determine whether the efficacy of TUSC2 plus carboplatin and pembrolizumab was antigen-specific, we performed in vitro stimulation of T cells with PMA and Ionomycin, and measured the percentage of IFN-γ+ T cells in different treatment groups (Fig. 7d-f). Scatter plots show that TUSC2 plus carboplatin and pembrolizumab increased IFN-γ+ T cell expression in all treatment groups compared to control, (*P < 0.05 vs TUSC2, **P < 0.005 vs carboplatin + pembrolizumab, ***P < 0.005 vs TUSC2 + pembrolizumab) (Fig. 7c). These results indicate that TUSC2 plus carboplatin and pembrolizumab may be effective for antigen-specific T cell responses.

In summary, the results of this study demonstrate the potential of TUSC2 plus carboplatin and pembrolizumab for improving T cell responses in KRAS/LKB1 lung metastases, with increased central and effector memory T cell function and antigen-specific T cell responses. Further studies are needed to confirm these findings and to explore the mechanism of action of this combination therapy.
sorted EM/CM+ T cells is shown in Fig. 7d. The level of IFN-γ expression in sorted memory T cells is shown in scatter plots (Fig. 7e). The percentage of IFN-γ+ T cells was significantly higher in CD3+EM/CM+ T cells and CD8+EM/CM+ T cells than their respective depleted counterparts, CD3+EM/CM− T and CD8+EM/CM− (Fig. 7f). CD4+EM/CM− T and CD4+EM/CM+ T cell had the lowest IFN-γ levels after stimulation with PMA or in co-culture with A549, suggesting that CD3+ and CD8+ EM/CM+ T cells are the main memory subsets for IFN-γ production. CD8+ EM/CM+ sorted T cells expressed high IFN-γ in every treatment group, although TUSC2 plus pembrolizumab and TUSC2+ carboplatin and pembrolizumab were the highest. Statistical analysis of IFN-γ responses from sorted Effector/Central memory T cells is shown in supplement Fig. 4. Taken together, the results show that the triple agent treatment induced strong antigen-specific T cells responses, which were greatly diminished when effector/central memory T cells were depleted.

**Discussion**

Loss of LKB1 activity is prevalent in KRAS mutant lung adenocarcinoma and promotes treatment-resistant tumors and poor survival[2,4,16]. Patient populations with these abnormalities do not respond nor derive long-term survival benefits from any therapy, including cytotoxic, cytostatic, immunotherapies, or their combinations[4,17–22]. The reason behind the insufficient clinical utility for this subtype is impaired immunogenicity, rather than...
treatment potency and efficacy. We previously investigated the relationship between TUSC2 and LKB1 using multiple NSCLC cell lines with or without LKB1 expression. TUSC2 showed selective sensitivity on LKB1-deficient cell lines as compared with wtLKB1 cell lines through upregulation of AMPK. In wtLKB1 expressing cells, LKB1 function is through direct activation of AMPK, thereby regulating apoptosis in response to energy stress. In LKB1-deficient cells, there is no LKB1-AMPK interaction and TUSC2 transfection in LKB1-deficient cells stimulated AMPK phosphorylation at Th172, the same residue used by LKB1 proteins for coupling with AMPK, raising the possibility that TUSC2 and LKB1 might compete with each other for binding to the same functional protein-binding site on AMPK. The mechanism of immunosuppression by LKB mutation is not well studied. However, LKB1 downregulates STING signaling in the tumor microenvironment, which suppresses innate immune activation and antigen presentation. We have shown previously and in the current study, that TUSC2 activates the innate immune response by inducing NK cell proliferation and Th1-mediated cytokine secretion. We also tested the therapeutic efficacy of TUSC2 in combination with the STING agonist cGAMP in the syngeneic CMT167 mouse model (KRAS mutant, aPD1 resistant) which showed enhanced antitumor activity, which was better than single-agent treatment. In this study, we have shown that TUSC2 immunogene therapy combined with carboplatin and pembrolizumab results in complete tumor eradication in over 65% of humanized mice implanted with KL NSCLC metastatic tumors. This impressive therapeutic benefit was reproducible in three blinded independent experiments. Tumor regression was also observed in the other fraction of animals but without complete eradication. This variation of tumor eradication might be explained by the variability of human immune reconstitution levels among humanized mice. A very important consideration is the advanced model used. Many preclinical studies evaluating therapeutic strategies use models that are not highly predictive of success in clinical trials. Therefore, most drugs tested in current preclinical models fail in the clinic. To address this major limitation, we have developed an improved humanized mouse model, derived from fresh CD34+ stem cell engraftment in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, without the onset of graft-versus-host disease (GVHD). We have demonstrated that this model replicates human tumor response to checkpoint blockade, mounts an immune response to tumor-associated antigens and not alloantigens, and is not stem cell donor-dependent for its immune response. Although humanized mouse models are an advanced preclinical model useful for testing the immune cellular response and changes in the tumor microenvironment following treatment, there are limitations of this model. Biological variation is greater in humanized mice compared with syngeneic mice. The level of engraftment of CD34+ stem cells derived from different donors and the level of different immune subpopulations differentiated from stem cells are not homogeneous in humanized mice, although humanized mice generated from the same donor are relatively homogeneous in their engraftment. Another limitation is the HLA-compatibility match among humanized mice, which are generated from different donors with different HLA haplotypes. A complete match of HLA is difficult unless the system is autologous, although in our previous study, we showed that the antitumor effect of checkpoint blockade immunotherapy does not depend on HLA-status. The hypothesis behind designing this innovative triple agent combination was that restoration of the multifactorial tumor suppressor gene TUSC2, deficient in 80% of NSCLC, will modulate the tumor immune microenvironment by changing its context from an immunosuppressive to immunostimulatory milieu, which will prime tumors for better response to chemo–immunotherapy. TUSC2 regulates a wide range of cellular processes, including cell cycle arrest and apoptosis, through inhibition of several kinases and modulation of the tumor microenvironment (TME). TUSC2 activates diverse innate and adaptive immune responses and downregulates PD-1/PD-L1 signaling to enhance sensitivity to checkpoint blockade by nivolumab and pembrolizumab.

For every randomized experiment, immunoprofiling analysis demonstrated high levels of reconstituted human immune cell populations in mice at different time points. Two weeks post-treatment, carboplatin plus pembrolizumab had similar antitumor activity as pembrolizumab did, which was significantly more effective than carboplatin alone. In week three, this dual combination was more effective than either single agent. However, this initial response, additive at best, was only transient and was followed by tumor regrowth. This model recapitulated the effect of carboplatin plus pembrolizumab reported in KL NSCLC patients. Carboplatin plus pembrolizumab efficacy was significantly inferior to that of the TUSC2 plus pembrolizumab combination, which was synergistic and durable. However, with the latter, the tumor regressed substantially but was not completely eradicated. TUSC2 and nivolumab synergistic antitumor response were also shown in this model.

Correlation of immunological features of TME revealed that TUSC2 plus carboplatin and pembrolizumab altered the immune contexture towards a pro-immune tumor microenvironment, which was not observed post carboplatin plus pembrolizumab treatment. There was a shift from a pre-existing immune response to a therapy-induced immune response. Reconstituted human CTLs, activated T cells, NK cells, and M1 macrophages were increased significantly, over all tested dual combinations. TUSC2 induces proliferation of NK cells through the upregulation of IL-15 signaling. We showed that TUSC2 nanovesicles were taken up by NK cells and lineage-negative myeloid cells and induced IL-15 secretion, which led to NK cell proliferation. Increased NK activity was associated with generating Th1 immunity in TME. TUSC2 also downregulates the PD1/PD-L1 signaling to enhance sensitivity to checkpoint blockade by nivolumab and pembrolizumab. TUSC2 and nivolumab do not reduce tumor cell immunosuppression, which could explain the enhanced antitumor activity by TUSC2 plus nivolumab treatment. However, TUSC2 plus carboplatin and pembrolizumab has significantly higher levels of reconstituted human dendritic cells were found, indicating a fully developed immune contexture. The latter are potent antigen-presenting cells.

On the other hand, TUSC2 plus carboplatin and pembrolizumab reduced tumor infiltration by Tregs, MDSCs, TAMs, and M2 Macrophages significantly. M2-polarized TAMs drive multiple protumorogenic processes, including immunosuppression, metastasis, and tumor survival. To our knowledge, this is the first study to characterize M1 and M2 macrophage polarization in the tumor microenvironment in humanized mice. These results indicate that TUSC2 combined with carboplatin and pembrolizumab affected many immune cell populations in the TME, significantly activating immune stimulatory while reducing immunosuppressive cell populations. Complete eradication of KL tumors by the triple agent combination was also associated with increased central memory (CM) and effector memory (EM) T cells, significantly more than those in the carboplatin plus pembrolizumab treatment group. Antigen-experienced T cells undergo differentiation to memory T cells downregulating CD45RA expression to CD45RO, which persist for a longer time and provide antitumor immunity as
compared with effector T cells. CD45RA antigens, identify functional characteristics of naive T lymphocytes, which lack HLA class II expression and do not respond to recall antigens, whereas their counterparts, CD45RO antigens, identify functional characteristics of memory T cells, which have high HLA class II expression and do respond to recall antigens. Both CM and EM cells provide strong antitumor immunity, which requires a very small amount of antigen exposure, compared to non-memory effector cells. A severe loss of T-memory cells during tumor progression has been reported, indicating a constant rivalry between cancer and T-memory cells. Hence, it is conceivable that by increasing the memory population, the tumor burden can be reduced. Sorted CM and EM T cells from treated humanized tumors showed that TUSC2 addition to carboplatin and pembrolizumab correlated with a significant increase of (a) IFN-γ levels, after tumor antigens exposure, indicating antigen-specific immune responses of the tested memory T cells, and (b) tissue-resident T-memory cells (TRM). TRM CD103+ CD8+ T cells are known to provide rapid protective immunity and are associated with a greater antitumor response. This suggests a specific role for these cells in promoting antigen-specific immune responses by the triple combination.

In conclusion, to be most effective, cancer therapy must take into account drug effects on the tumor microenvironment, which is dynamic and constantly shifting and which could be remodeled to enhance therapy. Collectively, our results demonstrate that TUSC2-stimulated immunity can sensitize resistant KL lung tumors to chemoimmunotherapy. The mechanisms of such synergy are multifaceted and are likely to involve other pathways, which remain to be investigated. The toxicity of carboplatin to immune cell populations can limit the extent of immune stimulation and lead to immunosuppression. Moreover, active expression and redistribution of PD-L1 to cancer cells may impair the therapeutic benefits of pembrolizumab. As carboplatin-induced tumor cell cytotoxicity and antitumor immune responses to carboplatin plus pembrolizumab wane, pro-tumor immune responses rebound. Addition of TUSC2, which downregulates PDL-1, could either induce de novo immunity or boost carboplatin plus pembrolizumab-stimulated immunity by providing alternative or complementary pathways to immune cell activation. This activity by TUSC2 induces strong antitumor immune responses, complementing and enhancing the immune stimulatory actions by carboplatin plus pembrolizumab. Importantly, the demonstrated therapeutic synergy of this triple agent combination supports the design of a clinical trial for the KL NSCLC subtype.

Methods

Cell line, cell culture, and maintenance. A549-luc human NSCLC cell line which carries KRAS/STK11 mutation was kindly provided by Dr. John Minna (The University of Texas Southwestern Medical Center, Dallas, TX). A549-luc cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (GE Healthcare Life Sciences, HyClone Laboratories) and 1% penicillin–streptomycin (Thermo Fisher Scientific) at 37 °C with 5% CO₂.

KRASG12/CMT167-luc cells were kindly provided by Frank R. Jirik (University of Calgary). CMT167 cells were cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% heat-inactivated fetal bovine serum (GE Healthcare Life Sciences, HyClone Laboratories) and 1% penicillin–streptomycin (Thermo Fisher Scientific) at 37 °C with 5% CO₂. Cell lines tested negative for mycoplasma before use.

The cells were injected for mycoplasma routinely by ELISA in a core lab in MD Anderson Cancer Center. Both cell lines were also authenticated by the core lab in MD Anderson Cancer Center. First 3–4-week-old mice were used in these studies. Mice were housed in microisolator cages under specific pathogen-free conditions in a dedicated humanized mouse room in the animal facility at The University of Texas MD Anderson Cancer Center. Mice were given autoclaved acidified water and fed a special diet (Uniprim diet). All animal use was conducted in accordance with the guidelines of the Animal Care and Use Committee of MD Anderson Cancer Center.

Umbilical cord blood processing. Human umbilical cord blood units for research were obtained from MD Anderson Cord Blood Bank under an Institutional Review Board (IRB)-approved protocol (Lab04-0249). The cord blood bank collects umbilical cord blood through voluntary donations from mothers following informed consent under the institutional approved IRB protocol. Cord blood bank collects human cord blood on daily basis from several Houston-area hospitals like Memorial Hermann Hospital, St. Joseph Medical Center, and the Woman’s Hospital of Texas, etc. Fresh cord blood units were delivered to the research lab within 24 h of harvest, and the cord blood units were HLA typed immediately at MD Anderson HLA typing core lab in MD Anderson Cancer Center. Both cell lines were also authenticated for ex vivo expansion, and the expanded cells were tagged with a NanoLuc lentivirus. The NanoLuc+ CD34+ cells were injected into mice for in vivo tracking.

Humanized NSG mice. After mononuclear cells were separated from human umbilical cord blood, CD34+ HSPCs were isolated using a direct CD34+ Microbead kit (Miltenyi Biotec). Three- to four-week-old NSG mice were irradiated with 250 cGy using a 137Cs gamma irradiator. Over 90% pure fraction isolated CD34+ HSPCs were injected intravenously, 24 h after irradiation, at a density of 1–2 × 10^6 CD34+ cells/mouse. The engraftment levels of human CD45+ cells were determined in the peripheral blood, as early as 4 weeks post CD34 injection, by flow cytometric quantification, as well as other human immune populations. Mice were considered as humanized (Hu-NSG mice). In-depth analysis of bone marrow and spleen tissue for human immune cell populations, including CD45+, CD3+ , CD4+, and CD8+ T cells, B cells, NK cells, and lineage-negative cells, was performed using a 10-color flow cytometry panel at weeks 6 and 9 post CD34+ engraftment. Hu-NSG mice from different cord blood donors with different levels of engraftment were randomized into every treatment group in all of the experiments. All Hu-NSG mice were verified for humanization before tumor implantation.

Human cell line xenografts development in mice. KRAS/LKB1 mutant A549-luc human NSCLC cell lines were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (GE Healthcare Life Sciences, HyClone Laboratories) and 1% penicillin–streptomycin (Thermo Fisher Scientific) at 37 °C with 5% CO₂. Cell lines tested negative for mycoplasma before use. To generate experimental lung metastases, 1 × 10^6 A549-luc cells were injected intravenously into NSG mice 6–8 weeks post CD34+ engraftment. Tumor growth was measured by quantifying bioluminescence intensity with an IVIS small animal imaging system (IVIS 200; Caliper Lifesciences).

TUSC2 nanovesicle formulation. TUSC2, previously known as FUSI, was encapsulated into DOTAP nanoparticles. The formulation is composed of 1, 2-bis(oleoyloxy)-3-(trimethylammonio)propane (DOTAP); cholesterol nanoparticles and a DNA plasmid expressing the TUSC2 tumor suppressor gene. The plasmid (PL 143/pKB2/FUSI 1) is 3968 bp and contains a kanamycin resistance gene, an origin of replication, and the human wild-type TUSC2 gene driven by a CMV promoter. The formulation is routinely manufactured in GMP facility following standard manufacturing protocols. The GMP grade TUSC2 nanovesicles were used as a study agent in this study.

Development and treatment of human A549 KRAS/LKB1 mutant xenografts in humanized mice. Seven days post A549 implantation in humanized mice, tumor growth was confirmed by IVIS imaging. TUSC2 nanovesicles were randomized into treatment and no-treatment groups on the basis of tumor density and donor HLA type. Eight to ten mice per group from multiple umbilical cord blood donors were used. The treatment groups were: untreated, TUSC2, carbo-platin, pembrolizumab, TUSC2 + carbo-platin, TUSC2 + pembrolizumab, carbo-platin + pembrolizumab, and TUSC2 + carbo-platin + pembrolizumab. TUSC2 (Genprex Inc) (25 μg/mouse) was injected intravenously every 3 days for three times; anti-PD1 agent pembrolizumab (Merck) or nivolumab (Bristol–Myers Squibb) (250 μg/mouse, intraperitoneally) every 3–4 days for 3 cycles; and carbo-platin (Teva Pharmaceuticals) (10 mg/kg, orally). TUSC2 encapsulated nanovesicles were validated for their expression by transfection into A549 cells before inoculation in humanized mice. A549 xenograft tumors were also generated in non-humanized NSG mice, which were treated alongside their humanized counterparts, as a control arm. Mice were monitored routinely for metastasis development with IVIS imaging. For immune analysis, mice from each treatment group were sacrificed 8 weeks post A549 injection, and organs were harvested for single-cell analysis. All animal experiments were carried out following approval by the MDACC institutional review board and were performed in accordance with the guidelines of the Animal Care and Use Committee of MD Anderson Cancer Center.

Mice used for humanization. NOD.Cg-PrkdcreIizPrkdcO1WtHsd (NSG) mice were obtained from The Jackson Laboratory. This strain’s eligibility for engraftment of human hematopoietic cells has been described. Female 3–4-week-old mice were used in these studies. Mice were housed in microisolator cages under specific pathogen-free conditions in a dedicated humanized mouse room in the animal facility at The University of Texas MD Anderson Cancer Center.
Received: 22 August 2021; Accepted: 1 February 2022; Published online: 24 February 2022

References

1. Skoulidis, F. et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer discovery 8, 822–835 (2018).
2. Facchetti, F. et al. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer 112, 62–68 (2017).
3. Bashir, F., Saravia, D., Fanfan, D., Cotta, J. A. & Lopes, G. Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer. J Clin Oncol 38 (2020).
4. Shire, N. J. et al. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. PloS one 15, e0238538 (2020).
5. Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England journal of medicine 346, 92–98 (2002).
6. Gandhi, L. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England journal of medicine 378, 2078–2092 (2018).
7. Jotte, R. et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol 15, 1351–1360 (2020).
8. Meraz, I. M. et al. TUSC2 Immune Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Synergistic Kras-Mutant Mouse Lung Cancer Models. Cancer immunology research 6, 163–177 (2018).
9. Cao, X. et al. TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget 8, 107621–107629 (2017).
10. Lu, C. et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PloS one 7, e34863 (2012).
11. Dai, R. et al. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PloS one 10, e0123967 (2015).
12. Meng, J. et al. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the Akt inhibitor MK2206 in KLK1-dependent manner. PloS one 8, e77607 (2013).
13. Crompton, J. G. et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer research 75, 296–305 (2015).
14. Meraz, I. M. et al. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer immunology research 7, 1267–1279 (2019).
15. Kitajima, S. et al. Suppression of STING Associated with LKB1 Loss in KRAS-Mutant Lung Adenocarcinoma. Cancer discovery 6, 315–329 (2016).
16. Scheffler, M. et al. K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. J Thorac Oncol 14, 610–616 (2019).
17. Skoulidis, F. et al. Association of STK11/LKB1 genomics alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J Clin Oncol 37, https://doi.org/10.1200/ICO.2019.37.15_suppl.102 (2019).
18. Jure-Kunkel, M. et al. Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC. J Clin Oncol 36, https://doi.org/10.1200/ICO.2018.36.15_suppl.3028 (2018).
19. Bange, E. et al. Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol 3, https://doi.org/10.1200/PO.18.00326 (2019).
20. Dafni, U., Tsonouri, Z., Vervita, K. & Peters, S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis. Lung Cancer 134, 127–140 (2019).
21. Langer, C. J. et al. Carboplatin and pembrolizumab with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncology 17, 1497–1508 (2016).
22. Frederickson, A. M. et al. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. Immunotherapy-UK 11, 407–428 (2019).
23. Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature reviews. Cancer 9, 563–575 (2009).
24. Wang, M. et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 32, 1537–1549 (2018).

25. Zhao, Y. et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 67, 1845–1854 (2018).

26. Chen, Y. B. et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 26, ARTN 78 (2019).

27. Hermiston, M. L., Xu, Z. & Weiss, A. CD45: A critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21, 107–137 (2003).

28. Sarkar, I., Pati, S., Dutta, A., Basak, U. & Sa, G. T-memory cells against cancer: Remembering the enemy. Cellular Immunology 338, 27–31 (2019).

29. Nizard, M. et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun 8, 15221 (2017).

30. Ganesan, A. P. et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol 18, 940–950 (2017).

31. Park, S. L., Gebhardt, T. & Mackay, I. K. Tissue-Resident Memory T Cells in Cancer Immunosurveillance. Trends in Immunology 40, 735–747 (2019).

32. Ishikawa, F. et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor (gamma) chain(null) mice. Blood 106, 1565–1573 (2005).

33. Ito, I. et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11, 733–739 (2004).

Acknowledgements
We acknowledge MDACC Flow cytometry and imaging core laboratory; MD Anderson animal facility for providing dedicated housing room for humanized mice; MD Anderson Cord Blood Core for providing fresh human cord blood units; MD Anderson HLA typing core; MD Anderson Department of Scientific Publication and Dara S Keener for her assistance with manuscript formatting and submission. This work was supported in part by the National Institutes of Health/National Cancer Institute through The University of Texas MD Anderson Cancer Center Support Grant (CCSG) CA-016672—Lung Program and Shared Core Facilities (J.A.R.); Specialized Program of Research Excellence (SPORE) Grant CA-070907 (J.A.R.); PDX development and trial grant U54CA-224065 (J.A.R.); Lung Cancer Moon Shot Program (J.A.R.), The University of Texas MD Anderson Cancer Center, sponsored research agreement from Genprex, Inc, has ownership interest (including stock, patents, etc.) in Genprex, Inc., and is a consultant/ advisory board member for Genprex, Inc. The other authors declare no competing interests.

Competing interests
J.A.R. reports receiving a commercial research grant from The University of Texas MD Anderson Cancer Center, sponsored research agreement from Genprex, Inc, has ownership interest (including stock, patents, etc.) in Genprex, Inc, and is a consultant/ advisory board member for Genprex, Inc. The other authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-022-03103-7.

Correspondence and requests for materials should be addressed to Ismail M. Meraz.

Peer review information Communications Biology thanks Ilaria Attili, David Barbie and the other, anonymous, reviewer for their contribution to the peer review of this work.

Primary Handling Editors: Toshiro Moroishi and Iive Rogers.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author contributions
Conception and design: I.M.M., M.M., J.A.R.. Development of methodology: I.M.M., M.M., E.S., J.A.R.. Acquisition of data (provided animals acquired and managed patients, provided facilities, etc.): I.M.M., M.M., F.M., R.S.. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): I.M.M., M.M., M.J.H., J.A.R.. Writing, review, and/or revision of the manuscript: I.M.M., M.M., E.S., J.A.R. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): I.M.M., M.M., J.A.R.. Study supervision: I.M.M., M.M., J.A.R..